AbbVie (ABBV) Declares $0.64 Quarterly Dividend; 3.1% Yield
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Speculative Bullish Options Flow in AbbVie (ABBV) as Management Presents at Healthcare Conference -Susquehanna
September 12, 2017 2:33 PM EDTSusquehanna options strategist Alison Edwards notes speculative bullish options flow in AbbVie (NYSE: ABBV), with management presenting at a healthcare conference, as an investor sold 2k Nov 85/92.5 call spreads at $4.78 (getting long the 92.5 strike options), possibly a buyer of 2,500 Jan 95 Calls for $1.50, while... More
AbbVie (ABBV) Reports Upadacitinib (ABT-494) Meets All Primary & Ranked Secondary Endpoints in Second Phase 3 Study
September 11, 2017 8:03 AM EDTAbbVie (NYSE: ABBV) today announced positive top-line results from the Phase 3 SELECT-BEYOND clinical trial evaluating upadacitinib (ABT-494), an investigational oral JAK1-selective inhibitor, in patients with moderate to severe rheumatoid arthritis (RA) who did not adequately respond or were intolerant to treatment with biologic DMARDs (bDMARDs).1 Results showed that after 12 weeks of treatment, both once-daily doses of upadacitinib (15 mg and 30 mg) met the study's primary endpoints of ACR20* and low disease activity (LDA)**.1 All ranked secondary endpoints were also achieved with both doses.1 Upadacitinib is not... More
